No Prescription |
 |
 | ||
|
ACOMPLIA Generic Rimonabant |
|
| ||
No Prescription » Prescription Drugs 1 » ACOMPLIA Generic Rimonabant Appetite suppressant Anti obesity drug. Acomplia is used complementary to diet and exercise to treat .obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the bloodA single pill has been found to stop both food and cigarette cravings enough to help people quit smoking and lose weight and could also help curb other unhealthy urges. In one study the medicine helped people who were overweight drop an average of 20 pounds and in another doubled the chances that smokers would quit. Acomplia contains the active ingredient Rimonabant. It is a selective CB1 Endocannabinoid Receptor Antagonist.Acomplia works by blocking receptors of a substance called cannabinoid 1 which stimulates hunger and other cravings in the brain and is also present in fat tissue. Sanofi argues that Acomplia can also prevent the risk ofCardiovascular disease.Patients with large waist circumference (102 cm in men and 88 cm in women) will mostly benefit from taking the drug.ACOMPLIAŤ (rimonabant) approved as an adjunct to diet and exercise for the treatment of obese patients (BMI ≥ 30 kg/m2) or overweight patients (BMI > 27 kg/m2) with associated risk factors such as type 2 diabetes or dyslipidemia.Side Effects:Acomplia was said to be well tolerated in early tests. The only relatively common side effects were mild GI side effects and dizziness and these were said to be transient. Buy ACOMPLIA Generic Rimonabant and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About ACOMPLIA Generic Rimonabant: Product Type: Prescription Drugs 1 ACOMPLIA ( Generic Rimonabant ) ACOMPLIA (Generic Rimonabant) Generic Rimonabant 20mg 28 Tabs 20mg 56 Tabs Generic Rimonabant ACOMPLIA
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
